NCT00022607View on ClinicalTrials.gov

Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

January 31, 2002

Study Completion Date

May 31, 2006

Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
BIOLOGICAL

bevacizumab

DRUG

thalidomide

Trial Locations (4)

90089

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles

95817

University of California Davis Cancer Center, Sacramento

91010-3000

City of Hope Comprehensive Cancer Center, Duarte

60637-1470

University of Chicago Cancer Research Center, Chicago

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

California Cancer Consortium

NETWORK

NCT00022607 - Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter